TG Therapeutics and Neuraxpharm sign $650 million commercialization deal for multiple sclerosis treatment
TG Therapeutics and Neuraxpharm have announced an agreement for the ex-US commercialization of BRIUMVI (ublituximab).
Archives for August 3, 2023
NK:IO raises £1.2 million to advance ‘pioneering’ NK cell therapy
NK:IO, a leader in natural killer (NK) cell biology applied to the development of potent, off-the-shelf cell therapies targeting solid tumors, has raised £1.2m.
Sygnature Discovery acquires NuChem Sciences
Sygnature Discovery has acquired NuChem Sciences, one of North America’s largest contract research organisations (CRO).